for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GSK plc

GSK.L

現在値

1,483.60GBp

変化

-8.80(-0.59%)

出来高

7,433,815

本日のレンジ

1,455.40

 - 

1,502.00

52週レンジ

1,280.92

 - 

2,280.50

∙ 約20分前の相場を表示しています。

適時開示

GSK Withdraws U.S. Marketing Authorisation For Blood Cancer Drug Blenrep

Nov 22 (Reuters) - GSK plc <GSK.L>::GSK PLC - BLENREP US UPDATE.GSK PLC - BLENREP US UPDATE.GSK - HAS INITIATED PROCESS FOR WITHDRAWAL OF US MARKETING AUTHORISATION FOR BLENREP.GSK: INITIATED PROCESS FOR WITHDRAWAL OF US MARKETING AUTHORISATION FOR BLENREP.GSK - REQUEST BASED ON OUTCOME OF DREAMM-3 PHASE III CONFIRMATORY TRIAL, WHICH DID NOT MEET REQUIREMENTS OF US FDA ACCELERATED APPROVAL REGULATIONS.GSK - PATIENTS CURRENTLY BEING TREATED WITH BLENREP SHOULD CONSULT THEIR HEALTHCARE PROVIDER.GSK - PATIENTS ALREADY ENROLLED IN BLENREP REMS PROGRAMME WILL HAVE OPTION TO ENROL IN A COMPASSIONATE USE PROGRAMME TO CONTINUE TO ACCESS TREATMENT.

GSK Announces Positive Phase IIa Study Results For New First-In-Class Candidate Medicine For TB Patients

Nov 14 (Reuters) - GSK plc <GSK.L>::GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS.GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED.GSK: GSK3036656 SHOWED EARLY BACTERICIDAL ACTIVITY WITH LOW, ONCE-DAILY ORAL DOSE AFTER 14 DAYS OF TREATMENT IN USERS WITH DRUG-SUSCEPTIBLE PULMONARY TB.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

GSK Says Sanofi-GSK COVID Booster Vaccine Approved By EU

Nov 10 (Reuters) - GSK plc <GSK.L>::GSK PLC - SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU.GSK - SANOFI AND GSK'S NEXT-GENERATION COVID-19 BOOSTER VACCINE VIDPREVTYN BETA APPROVED BY EUROPEAN COMMISSION.GSK - VACCINE APPROVED BY EUROPEAN COMMISSION AS A BOOSTER FOR PREVENTION OF COVID-19 IN ADULTS 18 YEARS OF AGE AND OLDER.

EMA Recommends Approval Of Vidprevtyn Beta As A Covid 19 Booster Vaccine

Nov 10 (Reuters) - EMA: :EMA: EMA RECOMMENDS APPROVAL OF VIDPREVTYN BETA AS A COVID 19 BOOSTER VACCINE: 10/11/2022.EMA- RECOMMENDED AUTHORISING COVID-19 VACCINE VIDPREVTYN BETA AS BOOSTER IN ADULTS PREVIOUSLY VACCINATED WITH MRNA OR ADENOVIRAL VECTOR COVID VACCINE.EMA: CHMP CONCLUDED BOOSTER DOSE OF VIDPREVTYN BETA IS EXPECTED TO BE AT LEAST AS EFFECTIVE AS COMIRNATY AT RESTORING PROTECTION AGAINST COVID-19.

Gsk Says IDMC Recommends Gepotidacin Early Efficacy Stop

Nov 3 (Reuters) - GSK plc <GSK.L>::GSK PLC - IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP.GSK PLC - IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP.GSK - GSK PLANS TO SUBMIT A NEW DRUG APPLICATION FOR GEPOTIDACIN TO US FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2023.GSK: TRIALS FOR GEPOTIDACIN STOPPED EARLY FOR EFFICACY FOLLOWING PRE-PLANNED INTERIM ANALYSIS BY INDEPENDENT DATA MONITORING COMMITTEE.

GSK Raises 2022 Guidance

Nov 2 (Reuters) - GSK plc <GSK.L>::GSK PLC - 3RD QUARTER RESULTS.GSK Q3 REVENUE 7.829 BILLION STG.GSK: 2022 GUIDANCE RAISED.GSK: EXPECT TO DELIVER GROWTH IN 2022 SALES OF BETWEEN 8% TO 10% CER AND GROWTH IN 2022 ADJUSTED OPERATING PROFIT OF BETWEEN 15% TO 17% CER.GSK: 2022 GUIDANCE EXCLUDES ANY CONTRIBUTION FROM COVID-19 SOLUTIONS.GSK - DIVIDEND OF 13.75P/SHARE DECLARED FOR Q3 2022. NO CHANGE TO EXPECTED DIVIDEND FROM GSK OF 61.25P/SHARE FOR FY 2022.GSK - Q3 2022 CONTINUING CASH GENERATED FROM OPERATIONS £1.9 BILLION.GSK - 2022 GUIDANCE EXCLUDES ANY CONTRIBUTION FROM COVID-19 SOLUTIONS.GSK: QTRLY TOTAL EPS 255.9P.GSK: QTRLY ADJUSTED EPS OF 46.9P.GSK - RAISING OUR FULL-YEAR GUIDANCE AND EXPECT GOOD MOMENTUM IN 2023.GSK: CHARGE OF £45 MILLION FOR SIGNIFICANT LEGAL MATTERS ARISING IN QUARTER, PRIMARILY REFLECTING PROVISION FOR INCREASED LEGAL FEES IN RELATION TO ZANTAC.GSK: ZANTAC LITIGATION HAS NOW BEEN CLASSIFIED AS A SIGNIFICANT LEGAL MATTER AND ALL PROSPECTIVE COSTS WILL THEREFORE BE INCLUDED AS AN ADJUSTING ITEM.GSK - MAJORITY OF EXPECTED COVID-19 SOLUTIONS SALES FOR 2022 HAVE BEEN ACHIEVED IN YEAR TO DATE.GSK - ANTICIPATE THAT SALES OF COVID-19 SOLUTIONS WILL BE SUBSTANTIALLY LOWER GOING FORWARD IN 2022.

GSK Provides Update On ContRAst Phase III Programme For Otilimab

Oct 27 (Reuters) - GSK plc <GSK.L>::GSK PLC - CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE.GSK PLC - CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE.GSK - GSK PROVIDES UPDATE ON CONTRAST PHASE III PROGRAMME FOR OTILIMAB IN TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS.GSK - CONTRAST PHASE IIL PROGRAMME ENROLLED A BROAD RANGE OF DIFFICULT-TO-TREAT PATIENTS.GSK - DATA FROM CONTRAST-3, DID NOT DEMONSTRATE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT OF ACR201 RESPONSE VERSUS PLACEBO AT WEEK 12.GSK - LIMITED EFFICACY DEMONSTRATED DOES NOT SUPPORT A SUITABLE BENEFIT/RISK PROFILE FOR OTILIMAB AS A POTENTIAL TREATMENT FOR RA.GSK - GSK HAS DECIDED NOT TO PROGRESS WITH REGULATORY SUBMISSIONS.

U.S. FDA panel backs GSK's anemia drug for kidney disease patients on dialysis

Oct 26 (Reuters) - GSK plc <GSK.L>::U.S. FDA ADVISERS SAY BENEFITS DO NOT OUTWEIGH RISKS FOR GSK'S DAPRODUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS NOT ON DIALYSIS.U.S. FDA ADVISERS SAY BENEFITS OUTWEIGH RISKS FOR GSK'S DAPRODUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS ON DIALYSIS.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

Lyell Immunopharma-Glaxosmithkline Informed Co As Part Of Strategic Actions, It Is Discontinuing Development Of Product Candidates Targeting Ny-Eso-1

Oct 24 (Reuters) - Lyell Immunopharma Inc <LYEL.O>::LYELL IMMUNOPHARMA-GLAXOSMITHKLINE INFORMED CO AS PART OF STRATEGIC ACTIONS, IT IS DISCONTINUING DEVELOPMENT OF PRODUCT CANDIDATES TARGETING NY-ESO-1.LYELL IMMUNOPHARMA INC - TERMINATION OF GSK AGREEMENT HAS MINIMAL IMPACT TO LYELL OPERATIONS.LYELL IMMUNOPHARMA - TERMINATION IS EFFECTIVE ON DECEMBER 24, 2022.LYELL IMMUNOPHARMA - GSK PROVIDED NOTICE OF DECISION TO TERMINATE THE LICENSE AND COLLABORATION AGREEMENT BETWEEN CO AND GSK.LYELL-TERMINATION OF GSK AGREEMENT DO NOT CHANGE CO’S GUIDANCE THAT CASH TO BE SUFFICIENT TO MEET WORKING CAPITAL,CAPITAL EXPENDITURE NEEDS INTO 2025.Further company coverage: LYEL.O. ((Reuters.Briefs@thomsonreuters.com;)).

Gsk Says Positive Headline Results From Perla, Phase 2 Trial Of Dostarlimab + Chemotherapy For Metastatic Non-Squamous Non-Small Cell Lung Cancer

Oct 5 (Reuters) - :GSK - PERLA PHASE 2 TRIAL EVALUATED DOSTARLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY.GSK- POSITIVE HEADLINE RESULTS FROM PERLA, PHASE II TRIAL OF DOSTARLIMAB + CHEMOTHERAPY FOR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC).GSK - FULL RESULTS FROM THE PERLA PHASE 2 TRIAL WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.GSK - SAFETY AND TOLERABILITY PROFILE OF DOSTARLIMAB IN PERLA PHASE II TRIAL WAS CONSISTENT WITH PREVIOUS CLINICAL TRIALS OF SIMILAR REGIMENS.GSK - COSTAR, THE PHASE II/III TRIAL COMBINING DOSTARLIMAB WITH COBOLIMAB, A TIM-3 ANTAGONIST, IN ADVANCED NSCLC ADVANCES TO PHASE III.GSK – PERLA TRIAL MET PRIMARY ENDPOINT OF OBJECTIVE RESPONSE RATE BY RESPONSE EVALUATION CRITERIA IN SOLID TUMOURS CRITERIA AS DETERMINED.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up